[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549678":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":27,"locations":37,"responsibleParty":55,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":26,"maxAge":67,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-dose Concentrations (1mg\u002Fml) of Bleomycin","EXPERIMENTAL","In this arm, patients with lymphatic malformations were treated by intracapsular injection with low-dose concentrations (1mg\u002Fml) of Bleomycin.",[13],"Drug: Bleomycin",{"label":15,"type":10,"description":16,"interventionNames":17},"High-dose Concentrations (2mg\u002Fml) of Bleomycin","In this arm, patients with lymphatic malformations were treated by intracapsular injection with high-dose concentrations (2mg\u002Fml) of Bleomycin.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Bleomycin","To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients",[15,9],[25],"Zeocin",null,[28,33],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},"Yi Ji, Ph.D.","CONTACT","+8618980606865","jijiyuanyuan@163.com",{"name":34,"role":30,"phone":35,"phoneExt":26,"email":36},"Min Yang, M.D.","+8615928411140","hx2014bsym@163.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"West China Hospital of Sichuan University","RECRUITING","Chengdu","Sichuan","610041","China","CN",{"type":47,"coordinates":48},"Point",[49,50],104.06667,30.66667,{"lat":50,"lon":49},[53,54],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},{"name":34,"role":30,"phone":35,"phoneExt":26,"email":36},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Yi Ji","Clinical Professor","100549678","phase-2-use-of-bleomycin-in-the-sclerotherapy-of-lymphatic-malformations-for-pediatric-patients-100549678",false,"NCT06437158","Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients","Efficacy and Safety of Different Concentrations of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients","Inclusion Criteria:\n\n* Male or female participants less than 14 years of age at the time of informed consent\u002Fassent form was signed.\n* Participants whose parents have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them.\n* Participants with LMs of all sites measured and confirmed via imaging at screening, with rapid progression, resluting in obvious symptoms or dysfunction, which could not be radically resected and could be treated by sclerotherapy.\n\nExclusion Criteria:\n\n* Penicillin allergy.\n* Vascular tumors or combined vascular malformations.\n* Participants who may have had surgical or sclerotherapy treatment by other hardeners.\n* LMs growing slowly, without obvious symptoms or dysfunction, which does not need to be treated prematurely.","ALL","14 Years",{"count":69,"type":70},200,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","Bleomycin has nowadays been more and more widely used in the sclerotherapy of LMs, which has been proven to be primarily dose dependent. The investigators aim to compare the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of LMs for pediatric patients.",[76],"Lymphatic Malformation",[76,21,78,79,80,81],"Sclerotherapy","Intracystic injection","High-dose concentrations","Low-dose concentrations","2024-05-31",{"date":84,"type":85},"2024-06-03","ACTUAL",{"date":87,"type":85},"2023-03-08",{"date":89,"type":70},"2026-12-31",{"name":5,"class":6},1]